• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rapport Therapeutics, Inc. - Common Stock (NQ:RAPP)

28.31 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Rapport Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline
January 07, 2026
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 18, 2025
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures
December 05, 2025
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting
November 25, 2025
New analysis examines RAP-219’s effect during the first month of treatment and consistency of efficacy over the treatment period, effectiveness across baseline disease severities, and impact on seizure... 
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update
November 06, 2025
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics to Participate in Upcoming Investor Conferences
November 05, 2025
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
September 11, 2025
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Announces Pricing of Public Offering of Common Stock
September 09, 2025
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Announces Proposed Public Offering of Common Stock
September 08, 2025
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures
September 08, 2025
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025
September 05, 2025
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update
August 07, 2025
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates
June 02, 2025
Phase 2a trial of RAP-219 in refractory focal epilepsy fully enrolled and on track for topline results in September 2025 
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference
May 27, 2025
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics to Host 2025 Investor and Analyst Day
May 21, 2025
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update
May 08, 2025
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics to Participate in Upcoming Investor Conferences
April 22, 2025
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting
March 21, 2025
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 11, 2025
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development
March 03, 2025
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics to Participate in Upcoming Investor Conferences
February 24, 2025
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders
January 09, 2025
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders
January 09, 2025
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures
December 06, 2024
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting
November 14, 2024
Poster presentations on Phase 2a trial seizure biomarker, preclinical, and Phase 1 clinical data 
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics Reports Third Quarter Financials and Provides Business Update
November 07, 2024
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November
November 04, 2024
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences
September 05, 2024
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen’s 4th Annual Novel Mechanisms in Neuropsychiatry Summit
August 29, 2024
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update
August 08, 2024
From Rapport Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap